ReviewEuropean journal of clinical pharmacology2026
Antimicrobial-induced hyponatremia: pathophysiological mechanisms, implicated agents, and clinical management strategies.
Review in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHyponatremia is a prevalent and serious electrolyte disorder affecting approximately 20% of hospitalized patients, significantly increasing morbidity and mortality. While common causes are well-documented, antimicrobial-induced hyponatremia is frequently underrecognized due to confounding infection-related factors. This review aims to systematically delineate the implicated antimicrobial agents, their underlying pathophysiological mechanisms, and clinical management strategies.
methodsA comprehensive literature search was conducted via PubMed for studies published between January 1, 2000, and August 22, 2025. Data were synthesized to categorize drugs based on risk levels, mechanisms of action, and clinical outcomes. Backward citation tracking was employed to identify additional pertinent cases and mechanistic studies.
resultsThe primary pathophysiological drivers identified are the syndrome of inappropriate antidiuresis (SIAD) and direct renal tubular dysfunction. High-risk agents include linezolid, trimethoprim-sulfamethoxazole and voriconazole. Other implicated agents include fluoroquinolones, vidarabine, rifabutin, azithromycin, aminoglycosides, colistin, nitrofurantoin and β-lactam antibiotics. Onset typically occurs within 2 to 14 days of therapy initiation. Key risk factors identified include advanced age (≥ 65 years), renal impairment, supratherapeutic dosing, large-volume hypotonic diluents, and concomitant use of diuretics or SSRIs.
conclusionAntimicrobial-induced hyponatremia is an important clinical entity that necessitates a high index of suspicion, particularly in older adults and polymedicated patients. Management focuses on the prompt identification and withdrawal of the offending agent, followed by symptom-stratified sodium correction. This review provides a practical guide to mitigate risks. Future prospective studies are needed to elucidate the mechanisms and clinical characteristics of antimicrobial-induced hyponatremia. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
42313206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.